Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document

Franck F. Rahaghi, Hassan M. Alnuaimat, Rana L.A. Awdish, Vijay P. Balasubramanian, Robert C. Bourge, Charles Dwayne Burger, John Butler, C. Gregory Cauthen, Murali M. Chakinala, Bennett P. deBoisblanc, Michael S. Eggert, Peter Engel, Jeremy Feldman, J. Wesley McConnell, Myung Park, Jeffrey S. Sager, Namita Sood, Harold I. Palevsky

Research output: Contribution to journalArticle

Abstract

In patients treated with macitentan (Opsumit_, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug-drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.

Original languageEnglish (US)
Pages (from-to)702-711
Number of pages10
JournalPulmonary Circulation
Volume7
Issue number3
DOIs
StatePublished - 2017

Fingerprint

Pulmonary Hypertension
Physicians
macitentan
Switzerland
Drug Interactions
Hospitalization
Drug Therapy
Pharmaceutical Preparations
Population

Keywords

  • Adverse events
  • Endothelin receptor antagonist
  • Therapy adherence

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH) : A Delphi consensus document. / Rahaghi, Franck F.; Alnuaimat, Hassan M.; Awdish, Rana L.A.; Balasubramanian, Vijay P.; Bourge, Robert C.; Burger, Charles Dwayne; Butler, John; Gregory Cauthen, C.; Chakinala, Murali M.; deBoisblanc, Bennett P.; Eggert, Michael S.; Engel, Peter; Feldman, Jeremy; Wesley McConnell, J.; Park, Myung; Sager, Jeffrey S.; Sood, Namita; Palevsky, Harold I.

In: Pulmonary Circulation, Vol. 7, No. 3, 2017, p. 702-711.

Research output: Contribution to journalArticle

Rahaghi, FF, Alnuaimat, HM, Awdish, RLA, Balasubramanian, VP, Bourge, RC, Burger, CD, Butler, J, Gregory Cauthen, C, Chakinala, MM, deBoisblanc, BP, Eggert, MS, Engel, P, Feldman, J, Wesley McConnell, J, Park, M, Sager, JS, Sood, N & Palevsky, HI 2017, 'Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document', Pulmonary Circulation, vol. 7, no. 3, pp. 702-711. https://doi.org/10.1177/2045893217721695
Rahaghi, Franck F. ; Alnuaimat, Hassan M. ; Awdish, Rana L.A. ; Balasubramanian, Vijay P. ; Bourge, Robert C. ; Burger, Charles Dwayne ; Butler, John ; Gregory Cauthen, C. ; Chakinala, Murali M. ; deBoisblanc, Bennett P. ; Eggert, Michael S. ; Engel, Peter ; Feldman, Jeremy ; Wesley McConnell, J. ; Park, Myung ; Sager, Jeffrey S. ; Sood, Namita ; Palevsky, Harold I. / Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH) : A Delphi consensus document. In: Pulmonary Circulation. 2017 ; Vol. 7, No. 3. pp. 702-711.
@article{4d28e2a9c5ee4d8c8debee2687b44ebc,
title = "Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document",
abstract = "In patients treated with macitentan (Opsumit_, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug-drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.",
keywords = "Adverse events, Endothelin receptor antagonist, Therapy adherence",
author = "Rahaghi, {Franck F.} and Alnuaimat, {Hassan M.} and Awdish, {Rana L.A.} and Balasubramanian, {Vijay P.} and Bourge, {Robert C.} and Burger, {Charles Dwayne} and John Butler and {Gregory Cauthen}, C. and Chakinala, {Murali M.} and deBoisblanc, {Bennett P.} and Eggert, {Michael S.} and Peter Engel and Jeremy Feldman and {Wesley McConnell}, J. and Myung Park and Sager, {Jeffrey S.} and Namita Sood and Palevsky, {Harold I.}",
year = "2017",
doi = "10.1177/2045893217721695",
language = "English (US)",
volume = "7",
pages = "702--711",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "University of Chicago Press",
number = "3",

}

TY - JOUR

T1 - Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH)

T2 - A Delphi consensus document

AU - Rahaghi, Franck F.

AU - Alnuaimat, Hassan M.

AU - Awdish, Rana L.A.

AU - Balasubramanian, Vijay P.

AU - Bourge, Robert C.

AU - Burger, Charles Dwayne

AU - Butler, John

AU - Gregory Cauthen, C.

AU - Chakinala, Murali M.

AU - deBoisblanc, Bennett P.

AU - Eggert, Michael S.

AU - Engel, Peter

AU - Feldman, Jeremy

AU - Wesley McConnell, J.

AU - Park, Myung

AU - Sager, Jeffrey S.

AU - Sood, Namita

AU - Palevsky, Harold I.

PY - 2017

Y1 - 2017

N2 - In patients treated with macitentan (Opsumit_, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug-drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.

AB - In patients treated with macitentan (Opsumit_, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug-drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.

KW - Adverse events

KW - Endothelin receptor antagonist

KW - Therapy adherence

UR - http://www.scopus.com/inward/record.url?scp=85032348172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032348172&partnerID=8YFLogxK

U2 - 10.1177/2045893217721695

DO - 10.1177/2045893217721695

M3 - Article

AN - SCOPUS:85032348172

VL - 7

SP - 702

EP - 711

JO - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 3

ER -